Evidence map›Paper›PMID 37846866›Full record

ArticleeLife2023

Identification of CD133

Kota Kaneko, Yan Liang, Qing Liu, Shuo Zhang, Alexander Scheiter, Dan Song, Gen-Sheng Feng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Complex Roles ofAnnual review of cancer biology · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Kota KanekoDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.ORCID 0009-0001-8595-8220
Yan LiangDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.
Qing LiuDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.
Shuo ZhangDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.
Alexander ScheiterDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.
Dan SongDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.
Gen-Sheng FengDepartment of Pathology, Department of Molecular Biology, and Moores Cancer Center, University of California at San Diego, La Jolla, United States.ORCID 0000-0003-1255-4708
University of California San Diego · US

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapyP01AG073084 · NIA · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI PETER D. ADAMS, GERALD SHADEL · 2021 to 2026
$13.6M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Tumor-promoting liver injuries and mechanismsR01CA239629 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2020 to 2024
$2.5M
Intra- and inter-cellular signals that drive hepato-oncogenesisR01CA236074 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2020 to 2024
$2.1M
A new mechanism of hepatocyte proliferation under stressR01DK128320 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FENG, GEN-SHENG · 2021 to 2024
$1.9M
JEOL JEM-1400Plus Transmission Electron MicroscopeS10OD023527 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FARQUHAR, MARILYN GIST · 2017 to 2017
$579k
NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA236074NCI NIH HHS R01 CA239629NIA NIH HHS P01 AG073084NIDDK NIH HHS R01 DK128320NIH HHS R01CA236074NIH HHS R01CA239629NIH HHS R01DK128320NIH HHS S10 OD023527NINDS NIH HHS P30 NS047101
6 · The paper itself

Abstract

CD133 (prominin 1) is widely viewed as a cancer stem cell marker in association with drug resistance and cancer recurrence. Herein, we report that with impaired RTK-Shp2-Ras-Erk signaling, heterogenous hepatocytes form clusters that manage to divide during mouse liver regeneration. These hepatocytes are characterized by upregulated CD133 while negative for other progenitor cell markers. Pharmaceutical inhibition of proliferative signaling also induced CD133 expression in various cancer cell types from multiple animal species, suggesting an inherent and common mechanism of stress response. Super-resolution and electron microscopy localize CD133 on intracellular vesicles that apparently migrate between cells, which we name 'intercellsome.' Isolated CD133

Indexed as

Liver NeoplasmsNeoplasm Recurrence, LocalAnimalsCell CommunicationHepatocytesMiceRNA, MessengerRNA, Messengercancer biologyCD133cell biologydrug resistancehumanintercellular communicationLiver regenerationmouseShp2/Ptpn11vesicle trafficking

Identifiers

PMID37846866
PMCPMC10581692
OpenAlexW4367846055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.